Saturday, 31 October 2026European Markets

AJAX And KINEPOLIS GROUP Have A High Dividend Yield And Return On Equity In The Communication Services Sector.

Loading stream...

(VIANEWS) - AJAX (AJAX.AS) is among this list of stock assets with the highest dividend rate and return on equity on the Communication Services sector.

Financial Asset Price Forward Dividend Yield Return on Equity
AJAX (AJAX.AS) €10.70 0.83% 17.95%
KINEPOLIS GROUP (KIN.BR) €47.00 0.55% 24.69%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. AJAX (AJAX.AS)

0.83% Forward Dividend Yield and 17.95% Return On Equity

AFC Ajax NV operates a football club primarily in the Netherlands. It also operates a stadium and an youth academy. The company was founded in 1900 and is based in Amsterdam, the Netherlands.

Earnings Per Share

As for profitability, AJAX has a trailing twelve months EPS of €2.13.

PE Ratio

AJAX has a trailing twelve months price to earnings ratio of 5.02. Meaning, the purchaser of the share is investing €5.02 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.95%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 6.4%, now sitting on 196.31M for the twelve trailing months.

More news about AJAX.

2. KINEPOLIS GROUP (KIN.BR)

0.55% Forward Dividend Yield and 24.69% Return On Equity

Kinepolis Group NV operates cinema complexes in Belgium, the Netherlands, France, Spain, Luxembourg, Switzerland, Poland, Canada, and the United States. The company sells cinema tickets, as well as events and vouchers to companies and publicity campaigns in the cinema; and beverages and snacks in the cinemas, as well as offers the self-service shop and other in-theatre sales concepts. It is also involved in international and domestic movie distribution, event organization, screen advertising, and property ownership activities; and the provision of technological services to third parties. The company has a portfolio of 110 cinema complexes, including 51 own complexes comprising 1,124 screens and approximately 200,000 seats. Kinepolis Group NV was incorporated in 1976 and is based in Brussels, Belgium.

Earnings Per Share

As for profitability, KINEPOLIS GROUP has a trailing twelve months EPS of €1.09.

PE Ratio

KINEPOLIS GROUP has a trailing twelve months price to earnings ratio of 43.12. Meaning, the purchaser of the share is investing €43.12 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 24.69%.

Volume

Today's last reported volume for KINEPOLIS GROUP is 6933 which is 67.25% below its average volume of 21170.

Revenue Growth

Year-on-year quarterly revenue growth grew by 25.1%, now sitting on 557.14M for the twelve trailing months.

Moving Average

KINEPOLIS GROUP's worth is higher than its 50-day moving average of €46.41 and higher than its 200-day moving average of €44.44.

Yearly Top and Bottom Value

KINEPOLIS GROUP's stock is valued at €47.00 at 01:30 EST, below its 52-week high of €49.30 and way higher than its 52-week low of €35.04.

More news about KINEPOLIS GROUP.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com